InVivoPlus anti-mouse TIGIT

Schorer M, Rakebrandt N, Lambert K, et al. TIGIT limits immune pathology during viral infections. Nat Commun. 2020,11(1):1288. doi: 10.1038/s41467-020-15025-1

Dixon KO, Schorer M, Nevin J, et al. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. J Immunol. 2018,200(8):3000-3007. doi: 10.4049/jimmunol.1700407

Burton BR, Britton GJ, Fang H, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014,5:4741. doi: 10.1038/ncomms5741

Chan CJ, Martinet L, Gilfillan S, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014,15(5):431-8. doi: 10.1038/ni.2850

Foks AC, Ran IA, Frodermann V, et al. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. PLoS One. 2013,8(12):e83134. doi: 10.1371/journal.pone.0083134

Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011,186(3):1338-42. doi: 10.4049/jimmunol.1003081